Literature DB >> 27105440

Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?

Sandip Basu1, Vikas Ostwal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27105440     DOI： 10.1097/MNM.0000000000000507

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


× No keyword cloud information.
  2 in total

1.  The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Authors:  Sandip Basu; Vikas Ostwal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-20       Impact factor: 9.236

Review 2.  Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.

Authors:  Samuel Adant; Girish M Shah; Jean-Mathieu Beauregard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.